Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Transient opioid use poses increased risk of acute COPD exacerbation

02 Sep 2019

The transient use of opioids is strongly associated with acute respiratory exacerbation of chronic obstructive pulmonary disease (COPD), and this risk increases with the average daily opioid dose, a study has found.

The analysis included 1,354 adult patients and 1,972 COPD exacerbation events, with 62.27 percent of the qualifying events having an opioid prescription during the 7-day period prior. The mean age of the patients at the index exacerbation event was 53.11 years.

Researchers examined the frequency and dose of opioid exposure in the 7 days before the exacerbation and compared with opioid exposure in 10 control windows, each 7 days long, before the exacerbation. They performed conditional logistic regression analysis, with adjustments for use of bronchodilators, corticosteroids, benzodiazepines and beta-blockers.

Results showed that opioid exposure within 7 days before an exacerbation significantly correlated with acute respiratory exacerbation (odds ratio [OR], 1.81, 95 percent CI, 1.60–2.05). Furthermore, every 25-mg increase in morphine equivalent daily dose was associated with about a 10-percent risk increase (OR, 1.11, 1.04–1.20).

According to the researchers, the unique nature of the current case-crossover design facilitated demonstration of the clinical significance of the immediacy of the opioids risk.

Nevertheless, further studies should be conducted to explore the short-term risk of concomitant use of opioids and benzodiazepines on respiratory events in the COPD population, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.